Anavex Life Sciences Corp.'s stock rises 50% as EMA reviews Alzheimer's drug blarcamesine. Click for my updated look at AVXL stock and why I have upgraded it.
Review of data from the trial found that the vaccine was not sufficiently effective at preventing invasive E coli disease ...
Gene Mack, Gain Therapeutics CEO, provides a look into the future of the company and the use of physics-based artificial ...
New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and ...
A new University of Kentucky Markey Cancer Center study provides important insights for future clinical trials in treating ...
9h
Positive IHL-42X PK findings for the treatment of Obstructive Sleep Apnea (OSA) support future 505(b)(2) New Drug Application (NDA) submissionNew OSA Clinical Advisory Board Announced; Appoints Dr. Al ...
The American Cancer Society's chief scientific officer outlines the group's research agenda, including a new project in ...
EXCLUSIVE: Retired David Mather was dealt a shocking blow when told his tiredness was stage-IV lung cancer - now a new UK ...
Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...
Otsuka has dumped a clutch of clinical cancer candidates on Valentine's day. | Otsuka has broken up with a clutch of clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback